lenalidomid stada 25mg tvrdá tobolka
stada arzneimittel ag, bad vilbel array - 17180 lenalidomid - tvrdá tobolka - 25mg - lenalidomid
lenalidomid stada 5mg tvrdá tobolka
stada arzneimittel ag, bad vilbel array - 17180 lenalidomid - tvrdá tobolka - 5mg - lenalidomid
lenalidomid zentiva 10mg tvrdá tobolka
zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 10mg - lenalidomid
lenalidomid zentiva 15mg tvrdá tobolka
zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 15mg - lenalidomid
lenalidomid zentiva 25mg tvrdá tobolka
zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 25mg - lenalidomid
lenalidomid zentiva 5mg tvrdá tobolka
zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 5mg - lenalidomid
tiacil 3/1 mg/ml oční kapky, roztok
virbac sa - antibiotika v kombinaci s jinými léky - oční kapky, roztok - 3/1mg/ml - antibiotika - kočky, psi
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mnohočetný myelom - antineoplastická činidla - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
aprepitant sandoz 125mg+80mg tvrdá tobolka
sandoz s.r.o., praha array - 16335 aprepitant; 16335 aprepitant - tvrdá tobolka - 125mg+80mg - aprepitant
aprepitant teva 125mg+80mg tvrdá tobolka
teva b.v., haarlem array - 16335 aprepitant; 16335 aprepitant - tvrdá tobolka - 125mg+80mg - aprepitant